Fluorescent risedronate analogue 800CW-pRIS improves tooth extraction-associated abnormal wound healing in zoledronate-treated mice

Hiroko Okawa; Takeru Kondo; Akishige Hokugo; Philip Cherian; Oskar Sundberg; Jesus J. Campagna; Boris A. Kashemirov; Varghese John; Shuting Sun; Frank H. Ebetino; Charles E. McKenna; Ichiro Nishimura

doi:10.1038/s43856-022-00172-x

Communications Medicine (Sep 2022)

Fluorescent risedronate analogue 800CW-pRIS improves tooth extraction-associated abnormal wound healing in zoledronate-treated mice

Hiroko Okawa,
Takeru Kondo,
Akishige Hokugo,
Philip Cherian,
Oskar Sundberg,
Jesus J. Campagna,
Boris A. Kashemirov,
Varghese John,
Shuting Sun,
Frank H. Ebetino,
Charles E. McKenna,
Ichiro Nishimura

Affiliations

Hiroko Okawa: Weintraub Center for Reconstructive Biotechnology, Division of Regenerative & Reconstructive Sciences, UCLA School of Dentistry
Takeru Kondo: Weintraub Center for Reconstructive Biotechnology, Division of Regenerative & Reconstructive Sciences, UCLA School of Dentistry
Akishige Hokugo: Weintraub Center for Reconstructive Biotechnology, Division of Regenerative & Reconstructive Sciences, UCLA School of Dentistry
Philip Cherian: BioVinc LLC
Oskar Sundberg: Department of Chemistry, University of Southern California
Jesus J. Campagna: Department of Neurology, David Geffen School of Medicine at UCLA
Boris A. Kashemirov: Department of Chemistry, University of Southern California
Varghese John: Department of Neurology, David Geffen School of Medicine at UCLA
Shuting Sun: Weintraub Center for Reconstructive Biotechnology, Division of Regenerative & Reconstructive Sciences, UCLA School of Dentistry
Frank H. Ebetino: BioVinc LLC
Charles E. McKenna: Department of Chemistry, University of Southern California
Ichiro Nishimura: Weintraub Center for Reconstructive Biotechnology, Division of Regenerative & Reconstructive Sciences, UCLA School of Dentistry

DOI: https://doi.org/10.1038/s43856-022-00172-x
Journal volume & issue: Vol. 2, no. 1
pp. 1 – 17

Abstract

Read online

Okawa et al. evaluate a fluorescent risedronate analogue, 800CW-pRIS, as a potential treatment for medication-related osteonecrosis of the jaw. The authors demonstrate an improvement in wound healing and inflammation with 800CW-pRIS pre-treatment in a mouse model of bisphosphonate-associated osteonecrosis following tooth extraction.

Published in Communications Medicine

ISSN: 2730-664X (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://www.nature.com/commsmed/

About the journal